Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study

Dan, Jiaqiang; Zhang, Yaojun; Huang, Junting; Chen, Minshan; Gao, Hengjun; Peng, Zhenwei; Xu, Li; Lau, W. Y.

doi:10.1016/j.ejso.2013.03.020

Cited by 57 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of HBV reactivation is 5.6% (7/125) in HBVrelated HCC patients who undergo RFA, and RFA therapy without antiviral treatment is a significant risk factor for HBV reactivation [55]. The results described above also suggest that antiviral treatment can significantly lower the chances of HBV reactivation in patients who received RFA compared with RFA patients that do not receive an antiviral treatment (0% vs. 7.6%).…”

Section: Antiviral Treatment In Ablative Therapymentioning

confidence: 57%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Section: Antiviral Treatment In Ablative Therapymentioning

confidence: 57%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

“…Numerous studies have shown that conformal radiotherapy [5–6], systemic chemotherapy [7–8], radiofrequency ablation [9] and transcatheter arterial chemoembolization (TACE) [10–11] can lead to HBV reactivation and hepatic dysfunction during treatment. Hepatectomy of patients with HBV-related HCC who are positive for HBV DNA in serum can lead to HBV reactivation during the perioperative period, and patients positive for HBV DNA or HBV surface antigen (HBsAg) may be at particularly high risk of reactivation [7, 9]. HBV reactivation can degrade liver function [12], aggravateliver cirrhosis [13], increase the risk of HBV-related HCC recurrence [14], and increase the incidence and severity of potentially life-threatening complications [15].…”

Section: Introductionmentioning

confidence: 99%

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma

Gong

Zhong

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The ability of antiviral therapy to reduce risk of post-hepatectomy hepatitis B virus (HBV) reactivation in patients negative for viral DNA is unclear. This prospective study involved 174 consecutive patients with hepatitis B virus related hepatocellular carcinoma who were negative for hepatitis B virus DNA in serum and who underwent hepatic resection. Hepatitis B virus reactivation occurred in 30 patients in the non-antiviral group (27.8%) but in only 2 patients in the antiviral group (3.0%, P < 0.001). Based on multivariate analysis, risk of hepatitis B virus reactivation was associated with minor hepatectomy and absence of antiviral therapy. Liver function indicators at one week after resection did not differ significantly between the two groups, or between patients who experienced hepatitis B virus reactivation or not. Nevertheless, alanine aminotransferase and albumin at 1 month after resection were significantly higher in the antiviral group than in the non-antiviral group, and they were significantly higher in patients who did not experience hepatitis B virus reactivation than in those who did. Therefore, patients with hepatitis B virus related hepatocellular carcinoma face substantial risk of hepatitis B virus reactivation after hepatectomy, even if they are negative for viral DNA at baseline. Antiviral therapy can reduce the risk of reactivation, helping improve liver function after surgery. (Clinicaltrials.gov registration number: NCT02829359).

show abstract

“…For HBV-related HCC patients, after the therapy of surgical resection or RFA, antiviral therapy is recommended. Prophylactic antiviral therapy for HBVrelated HCC can decrease the incidence of post-treatment HBV reactivation (53). Meta-analysis also demonstrated that antiviral therapy improves the survival rate and decreases recurrences following curative treatment of HBV-related HCC (54).…”

Section: Antiviral Therapymentioning

confidence: 99%

Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection

Zhu

Huang

Liao

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma is the most common malignancy in liver, is also a global problem and is the fourth most commonly diagnosed cancers among men and the fourth leading causes of cancer death among both men and women in China. Liver resection or hepatic resection and radiofrequency ablation is widely accepted as a first-line surgical approach for hepatocellular carcinoma in China. However, the indications of radiofrequency ablation or hepatic resection are different and not unified in China. In this article, we review the current status of hepatic resection and radiofrequency ablation therapies in hepatocellular carcinoma management in China.

show abstract

Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study

Cited by 57 publications

References 29 publications

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma

Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection

Contact Info

Product

Resources

About